Sermorelin Dosage: Timing, Frequency, Titration, and Monitoring

Sermorelin dosage questions come up constantly, and the honest answer starts with context: sermorelin no longer has a current FDA label for adults. It was approved as Geref for children with idiopathic growth hormone deficiency, and that product was discontinued in the U.S. in 2008. Today sermorelin is prescribed through compounding, and dose amounts are set by the prescriber for the specific preparation. What is consistent across protocols is the structure — when doses are given, how often, how response is measured, and how long therapy runs. That structure is what this guide covers.

For what sermorelin is and how it works, see our sermorelin overview.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Why There Is No Single Standard Sermorelin Dose

• No current adult label. The only approved labeling was pediatric, for a specific deficiency state.
• Formulations differ. Compounded sermorelin varies in vial strength, diluent volume, and route, so a number that is correct for one preparation is wrong for another.
• Response varies. Sermorelin works through the patient's own pituitary. Age, body composition, sleep, and metabolic health all change how much GH a given dose releases.

For those reasons the prescriber sets the amount, and the protocol is adjusted based on measured IGF-1 rather than fixed in advance. Dose amounts should always be confirmed with the compounding partner for the specific formulation.

The Historical Labeled Regimen

Geref was given by subcutaneous injection once daily at bedtime, with the dose calculated from the child's body weight. Two features of that regimen carried over into how sermorelin is used today: daily dosing, because the peptide is cleared within minutes, and bedtime timing, to coincide with the largest natural GH pulse of the day.

How Sermorelin Dosing Protocols Are Structured

Route

Subcutaneous injection is the reference route. Oral, sublingual, and nasal preparations are offered by some compounding pharmacies, but peptides of this size are poorly absorbed through those routes, so nominal doses are not interchangeable with injection. The trade-offs are covered in our comparison of peptide delivery methods.

Timing

• Bedtime is the most common choice. The largest spontaneous GH pulse occurs early in sleep, and a bedtime dose reinforces it.
• Away from food. Glucose, insulin, and circulating fatty acids blunt GH release. Protocols typically place the dose at least a couple of hours after the last meal.

Frequency

Because sermorelin's half-life is measured in minutes, protocols use daily or near-daily injections rather than weekly dosing. Some clinicians build in scheduled days off; the rationale is to preserve pituitary responsiveness, though controlled evidence comparing schedules is limited.

Titration

Protocols commonly start conservatively and adjust based on:

• IGF-1 measured after several weeks, compared against the age- and sex-adjusted reference range
• Tolerability, particularly flushing, fluid retention, or joint discomfort
• Clinical response over months rather than weeks

The goal is an IGF-1 in the physiological range for the patient's age, not the highest achievable value.

Duration

GH-axis effects on body composition develop slowly. Protocols are typically evaluated over three to six months before judging response, with periodic reassessment thereafter. Treatment is not usually open-ended without follow-up.

Monitoring During Sermorelin Therapy

What to watch for between visits is covered in sermorelin side effects.

Reconstitution and Measuring a Dose

Compounded sermorelin is usually supplied as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water. The amount of diluent determines the concentration, which determines how many syringe units deliver the prescribed dose. Errors here are one of the most common sources of dosing mistakes.

• How to reconstitute peptides walks through the process step by step.
• The peptide reconstitution calculator converts vial strength and diluent volume into units on a U-100 insulin syringe.
• Bacteriostatic water covers the diluent itself, and peptide storage covers refrigeration and shelf life after mixing.

Combining Sermorelin With Other Peptides

Sermorelin is sometimes paired with a ghrelin-receptor agonist such as ipamorelin. The two act through different pituitary receptors, and the combined GH pulse is larger than either alone. Combining also compounds the need for IGF-1 monitoring. The differences between the two peptides are covered in Sermorelin vs Ipamorelin.

Adjusting for the Individual Patient

Because sermorelin works through the patient's own pituitary, several factors change how protocols are set and interpreted:

• Age. GH output declines with age, and so does the magnitude of response to GHRH. Older patients may show a smaller IGF-1 rise at a given dose.
• Body fat and insulin status. Obesity and hyperinsulinemia blunt GH secretion. Improving sleep, activity, and insulin sensitivity often matters as much as the peptide.
• Sex. Estrogen affects GH and IGF-1 dynamics, and oral estrogen in particular lowers IGF-1. Reference ranges and interpretation should account for this.
• Sleep. The nocturnal GH pulse depends on slow-wave sleep. Poor sleep undermines the rationale for bedtime dosing.
• Concurrent therapies. Thyroid status, glucocorticoids, and other hormone therapy all influence the GH axis and should be reviewed at baseline.

Stopping Sermorelin

Sermorelin does not suppress the pituitary the way exogenous growth hormone suppresses endogenous GH production, so there is no taper requirement based on axis suppression. When therapy stops, GH and IGF-1 return toward their pretreatment levels over time, and any body-composition changes that depended on them tend to fade without the training and lifestyle factors that support them.

Common Dosing Mistakes

• Dosing right after a meal, which blunts the GH response.
• Miscalculating concentration after reconstitution.
• Judging response too early. Body-composition changes take months.
• Titrating by feel instead of IGF-1.
• Assuming oral or nasal doses equal injected doses.

Regulatory Status

Our FDA peptide status tracker lists sermorelin in Category 1 (under evaluation) for 503A compounding. Newtropin connects licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers. For how sermorelin fits among the other growth hormone peptides, see peptides for muscle growth.

Frequently Asked Questions

What is the standard sermorelin dosage?

There is no current FDA-labeled adult dose. Sermorelin is prescribed through compounding, and the amount is set by the prescriber for the specific formulation and adjusted based on IGF-1.

When is the best time to take sermorelin?

Most protocols use bedtime dosing on an empty stomach, to align with the natural nocturnal GH pulse and avoid the blunting effect of recent food.

How often is sermorelin injected?

Because it is cleared within minutes, sermorelin is typically injected daily or near-daily rather than weekly.

How long does it take for sermorelin to work?

IGF-1 changes can be measured within weeks. Body-composition and other clinical effects are usually evaluated over three to six months.

Can sermorelin be taken orally?

Oral and sublingual preparations exist, but absorption is much lower than with injection, so doses are not interchangeable.

How do I know if the sermorelin dose is right?

IGF-1 is the objective marker. The prescriber aims for a value within the age-adjusted reference range, alongside tolerability and clinical response.